Piper Sandler on Praxis Precision Medicines (PRAX): 'Two Major Wins Set the Stage for Multiple Potential Approvals in 2026'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $450.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
